While influenza vaccines aim to decrease the incidence of severe influenza among high-risk groups, evidence of influenza vaccine effectiveness (IVE) among the influenza vaccine target population is sparse. We conducted a multicentre test-negative case–control study to estimate IVE against hospitalised laboratoryconfirmed influenza in the target population in 18 hospitals in France, Italy, Lithuania and the Navarre and Valencia regions in Spain. All hospitalised patients aged ≥18 years, belonging to the target population presenting with influenza-like illness symptom onset within seven days were swabbed. Patients positive by reverse transcription polymerase chain reaction for influenza virus were cases and those negative were controls. Using logistic regression, we calculated IVE for each influenza virus subtype and adjusted it for month of symptom onset, study site, age and chronic conditions. Of the 1,972 patients included, 116 were positive for influenza A(H1N1)pdm09, 58 for A(H3N2) and 232 for influenza B. Adjusted IVE was 21.3% (95% confidence interval (CI): -25.2 to 50.6; n=1,628), 61.8% (95% CI: 26.8 to 80.0; n=557) and 43.1% (95% CI: 21.2 to 58.9; n=1,526) against influenza A(H1N1) pdm09, A(H3N2) and B respectively. Our results suggest that the 2012/13 IVE was moderate against influenza A(H3N2) and B and low against influenza A(H1N1) pdm09.

Rondy, M., Launay, O., Puig-barbera, J., Gefenaite, G., Castilla, J., De Gaetano Donati, K., Galtier, F., Hak, E., Guevara, M., Costanzo, S., Moren, A., Lenzi, N., Lesieur, Z., Bonmarin, I., Duval, X., Costa, Y., Kanagaratnam, A., Yazdapanah, Y., Caseris, M., Dournon, N., Papo, T., Dossier, A., Becheur, H., Pelletier, A. -., Mal, H., Marceau, A., Aubier, M., Bories, R., Casalino, E., Choquet, C., Houhou, N., Loulergue, P., Kanaan, R., Dumas, F., Postil, D., Alcolea, S., Rogez, S., Vanhaems, P., Regis, C., Merle, C., Foulongne, V., Ray, M., Maugueret-doublet, V., Bourdin, A., Landreau, L., Konate, A., Corne, P., Sebbane, M., Klouche, K., Leglise, M. -., Valette, M., Lina, B., Carrat, F., Chau, F., Diez-domingo, J., Escribano-lopez, B., Arnedo-pena, A., Ruiz-garcia, M., Tortajada-girbes, M., Munuera, C. C., Sanudo, J. B., Larrea-gonzalez, R., Gil-guillen, V., Schwarz-chavarri, G., Rahamat-langendoen, J., Niesters, H., Ambrozaitis, A., Jancoriene, L., Mickiene, A., Kuliese, M., Velyvyte, D., Stolk, R. P., Zagminas, K., Ezpeleta, C., Chamorro, J., Artajo, P., Lameiro, F., Navascues, A., Ortega, M., Torres, M., Irure, J. J. G., Irisarri, F., Cenoz, M. G., Martinez-baz, I., Cauda, R., Donato, C., Santangelo, R., Perlasca, F., Fichera, G., Dara, M., Iacoviello, L., Olivieri, M., 2012/13 influenza vaccine effectiveness against hospitalised influenza A(H1N1)pdm09, A(H3N2) and B: estimates from a European network of hospitals, <<EUROSURVEILLANCE>>, 2015; 20 (2): 9-20. [doi:10.2807/1560-7917.ES2015.20.2.21011] [http://hdl.handle.net/10807/171181]

2012/13 influenza vaccine effectiveness against hospitalised influenza A(H1N1)pdm09, A(H3N2) and B: estimates from a European network of hospitals

de Gaetano Donati, K.;Cauda, R.;Santangelo, R.;Fichera, G.;
2015

Abstract

While influenza vaccines aim to decrease the incidence of severe influenza among high-risk groups, evidence of influenza vaccine effectiveness (IVE) among the influenza vaccine target population is sparse. We conducted a multicentre test-negative case–control study to estimate IVE against hospitalised laboratoryconfirmed influenza in the target population in 18 hospitals in France, Italy, Lithuania and the Navarre and Valencia regions in Spain. All hospitalised patients aged ≥18 years, belonging to the target population presenting with influenza-like illness symptom onset within seven days were swabbed. Patients positive by reverse transcription polymerase chain reaction for influenza virus were cases and those negative were controls. Using logistic regression, we calculated IVE for each influenza virus subtype and adjusted it for month of symptom onset, study site, age and chronic conditions. Of the 1,972 patients included, 116 were positive for influenza A(H1N1)pdm09, 58 for A(H3N2) and 232 for influenza B. Adjusted IVE was 21.3% (95% confidence interval (CI): -25.2 to 50.6; n=1,628), 61.8% (95% CI: 26.8 to 80.0; n=557) and 43.1% (95% CI: 21.2 to 58.9; n=1,526) against influenza A(H1N1) pdm09, A(H3N2) and B respectively. Our results suggest that the 2012/13 IVE was moderate against influenza A(H3N2) and B and low against influenza A(H1N1) pdm09.
Inglese
Rondy, M., Launay, O., Puig-barbera, J., Gefenaite, G., Castilla, J., De Gaetano Donati, K., Galtier, F., Hak, E., Guevara, M., Costanzo, S., Moren, A., Lenzi, N., Lesieur, Z., Bonmarin, I., Duval, X., Costa, Y., Kanagaratnam, A., Yazdapanah, Y., Caseris, M., Dournon, N., Papo, T., Dossier, A., Becheur, H., Pelletier, A. -., Mal, H., Marceau, A., Aubier, M., Bories, R., Casalino, E., Choquet, C., Houhou, N., Loulergue, P., Kanaan, R., Dumas, F., Postil, D., Alcolea, S., Rogez, S., Vanhaems, P., Regis, C., Merle, C., Foulongne, V., Ray, M., Maugueret-doublet, V., Bourdin, A., Landreau, L., Konate, A., Corne, P., Sebbane, M., Klouche, K., Leglise, M. -., Valette, M., Lina, B., Carrat, F., Chau, F., Diez-domingo, J., Escribano-lopez, B., Arnedo-pena, A., Ruiz-garcia, M., Tortajada-girbes, M., Munuera, C. C., Sanudo, J. B., Larrea-gonzalez, R., Gil-guillen, V., Schwarz-chavarri, G., Rahamat-langendoen, J., Niesters, H., Ambrozaitis, A., Jancoriene, L., Mickiene, A., Kuliese, M., Velyvyte, D., Stolk, R. P., Zagminas, K., Ezpeleta, C., Chamorro, J., Artajo, P., Lameiro, F., Navascues, A., Ortega, M., Torres, M., Irure, J. J. G., Irisarri, F., Cenoz, M. G., Martinez-baz, I., Cauda, R., Donato, C., Santangelo, R., Perlasca, F., Fichera, G., Dara, M., Iacoviello, L., Olivieri, M., 2012/13 influenza vaccine effectiveness against hospitalised influenza A(H1N1)pdm09, A(H3N2) and B: estimates from a European network of hospitals, <<EUROSURVEILLANCE>>, 2015; 20 (2): 9-20. [doi:10.2807/1560-7917.ES2015.20.2.21011] [http://hdl.handle.net/10807/171181]
File in questo prodotto:
File Dimensione Formato  
171181oa.pdf

accesso aperto

Tipologia file ?: Versione Editoriale (PDF)
Licenza: Non specificato
Dimensione 247.83 kB
Formato Unknown
247.83 kB Unknown Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/171181
Citazioni
  • ???jsp.display-item.citation.pmc??? 21
  • Scopus 25
  • ???jsp.display-item.citation.isi??? 13
social impact